We found that the status of tumor PD-L2 was not significantly associated with survival outcome in early-stage colon carcinoma patients (79.4% vs 79.6%, p = 0.833, Fig. 1F), patients without PNI (p = 0.014) or MMR-proficient patients (p = 0.001, Table 2). Here, PDCD1LG2 is linked to colon carcinoma.